𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Non-small cell lung cancer: how oncologists want to be treated

✍ Scribed by William J. Mackillop; Brian O'Sullivan; Glen K. Ward

Publisher
Elsevier Science
Year
1987
Tongue
English
Weight
657 KB
Volume
13
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Infections in patients with non-small-ce
Infections in patients with non-small-cell lung cancer treated with intensive induction chemotherapy
✍ Fuks, Joachim Z. ;Patel, Halesh ;Hornedo, Javier ;Van Echo, David A. ;Moody, Mar 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 612 KB

The records of 65 consecutive patients with non-small-cell lung cancer (NSCLC) treated with intensive induction chemotherapy were reviewed to study the infectious complications during therapy and to analyze the relationship of the frequency of infections to various predisposing factors. A total of 4

ATM sequence variants associate with sus
ATM sequence variants associate with susceptibility to non-small cell lung cancer
✍ Hushan Yang; Margaret R. Spitz; David J. Stewart; Charles Lu; Ivan P. Gorlov; Xi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 97 KB 👁 1 views

## Abstract __ATM__ gene mutations have been implicated in many human cancers. However, the role of __ATM__ polymorphisms in lung carcinogenesis is largely unexplored. We conducted a case‐control analysis of 556 Caucasian non‐small‐cell lung cancer (NSCLC) patients and 556 controls frequency‐matche

Establishment of a human non-small cell
Establishment of a human non-small cell lung cancer cell line resistant to gefitinib
✍ Fumiaki Koizumi; Tatsu Shimoyama; Fumiko Taguchi; Nagahiro Saijo; Kazuto Nishio 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 672 KB

## Abstract The epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitor gefitinib (Iressa®, ZD1839) has shown promising activity preclinically and clinically. Because comparative investigations of drug‐resistant sublines with their parental cells are useful approaches to identifying the m

MDM2 SNP309 contributes to non-small cel
MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese
✍ Jing Dong; Binhui Ren; Zhibin Hu; Jiaping Chen; Lingmin Hu; Juncheng Dai; Guangf 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract Murine double minute 2 (MDM2) is a negative regulator of the tumor suppressor gene __p53__. Single nucleotide polymorphisms in __MDM2__ and __p53__ can affect patient's response to chemotherapy as well as overall survival of many cancers. This study aimed to assess the associations betw

PRIMA-1 synergizes with adriamycin to in
PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells
✍ R. Magrini; D. Russo; L. Ottaggio; G. Fronza; A. Inga; P. Menichini 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 1 views

## Abstract p53‐dependent apoptosis is important for the efficacy of cancer treatment, and tumors carrying mutant p53 are often resistant to chemotherapy. Non‐small cell lung cancer (NSCLC) cells generally exhibit resistance to apoptosis following treatment with many cytotoxic drugs. The new molecu